5 REASONS TO ADD SIERRA ONCOLOGY TO YOUR PORTFOLIO 5 REASONS TO ADD SIERRA ONCOLOGY TO YOUR PORTFOLIO
$SRRA
Sierra Oncology, Inc. (NASDAQ: SRRA) a late-stage biopharmaceutical company, announced positive topline results from a pivotal Phase 3 MOMENTUM study, which was evaluating momelotinib (MMB), an orally bioavailable JAK1, JAK2 and ACVR1 / ALK2 inhibitor, intended for the treatment of myelofibrosis in patients who are symptomatic and anemic and previously treated with an approved JAK inhibitor.
The Company intends to file a New Drug Application (NDA) for momelotinib for treatment of myelofibrosis, who are symptomatic and anemic in Q2,2022.
We bring you 5 reasons why you should consider adding this to your portfolio.
[url=https://www.aviseanalytics.com/5-reasons-to-add-sierra-oncology-to-your portfolio/]Read on to know more:[/url]
https://www.aviseanalytics.com/5-reasons-to-add-sierra-oncology-to-your-portfolio/